ClinicalTrials.gg
RecruitingNCT07934446Updated Nov 13, 2026

High-Frequency Ultrasound Monitoring of Cutaneous Leishmaniasis During Treatment

An observational study in Cutaneous Leishmaniasis, sponsored by University of Brasilia. Recruiting at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by University of Brasilia · Observational

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.
Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Leishmaniasis, Cutaneous with a site in Brazil — 3 open to participants now, 3 under way, 1 of them phase 3. Leishmaniasis, Cutaneous · Brazil.

Started
2025
the only one that year
Observational
Only one
of the 18
Registered
18th of 18
by date
Lead sponsor
3 of 18
University of Brasilia

Among the 18 studies in Leishmaniasis, Cutaneous with a site in Brazil, this one is the only one that started in 2025, is the only observational one, and was the 18th registered.

Leishmaniasis, Cutaneous

104 studies on the registry are indexed under Leishmaniasis, Cutaneous; 19 are open to participants now.

Browse Leishmaniasis, Cutaneous studies →

Open to participants now

3 of the 18 studies in Leishmaniasis, Cutaneous with a site in Brazil are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 11 Leishmaniasis, Cutaneous studies recruiting now, 4 (36%) set no upper age limit and 3 (27%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Leishmaniasis, Cutaneous with a site in Brazil, or all of them as a file.
02

Study summary

This prospective observational cohort study evaluates changes in high-frequency skin ultrasound findings in patients with cutaneous leishmaniasis receiving routine clinical treatment at the University Hospital of Brasilia, Brazil. The primary outcome is clinical cure assessed three months after completion of treatment. Ultrasonography will characterize dermal and hypodermal thickness, echogenicity and color Doppler vascular signals over repeated examinations. Associations of baseline clinical, histopathological, and ultrasound findings with healing will be investigated. Participants will be followed for 12 months from treatment initiation to evaluate their clinical course, including relapse.

Read the detailed description

Patients with cutaneous leishmaniasis will be enrolled consecutively in a prospective, single-center observational cohort at the Leishmaniasis Outpatient Clinic, Dermatology Service, University Hospital of Brasilia (HUB), Brazil. The treating clinicians determine antiparasitic treatment according to routine care; the research protocol does not assign treatment.

The diagnosis will follow an established composite reference standard based on a compatible clinical presentation and parasitological confirmation (for example, direct smear, culture, molecular detection, or amastigotes identified on histopathology), or corroborating non-parasitological findings when parasitological confirmation is unavailable. Histopathological specimens obtained at baseline as part of diagnostic care are available for retrospective review and correlation with clinical and ultrasonographic findings.

Serial high-frequency ultrasound using a Clarius L20 handheld linear scanner (8-20 MHz), including B-mode and color Doppler examination, will assess lesion morphology, echogenicity, dermal and hypodermal thickness, and vascularity. The ultrasound schedule is at days 0, 15, 30, 45, and 90 from initiation of treatment. Clinical follow-up will occur during treatment and for up to 12 months from treatment initiation. No investigational drugs or treatment allocation are part of this observational study.

The primary endpoint is clinical cure at three months following completion of treatment, assessed by clinical examination. Secondary analyses will characterize longitudinal ultrasound changes, the relationship of baseline clinical and histopathological findings with ultrasound features, persistence of sonographic abnormalities at initial clinical cure assessment, and exploratory association of sonographic characteristics with subsequent relapse. Ultrasound findings will not themselves define clinical cure or demonstrate parasite viability.

03

Conditions studied

  • Cutaneous Leishmaniasis

Keywords

  • Cutaneous leishmaniasis
  • Leishmania
  • Dermatologic ultrasound
  • High-frequency ultrasonography
  • Color Doppler
  • Clinical healing
  • Histopathology
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals of any age with confirmed cutaneous leishmaniasis evaluated in the Leishmaniasis Outpatient Clinic at University Hospital of Brasilia, Brazil.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cutaneous lesions clinically compatible with leishmaniasis and diagnosis confirmed according to the study's composite reference standard.
  • Evaluation at the Leishmaniasis Outpatient Clinic of the University Hospital of Brasilia.
  • Written from adults or a legally authorized representative's permission and age-appropriate assent for minors, as applicable.

Exclusion criteria

Exclusion Criteria:

  • An alternative diagnosis established during diagnostic assessment.
  • No confirmed cutaneous leishmaniasis diagnosis.

Additional exclusions, if any, must be verified against the approved study protocol before release.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (estimated)

Groups and cohorts

  • Patients With Cutaneous Leishmaniasis

    Patients with confirmed cutaneous leishmaniasis receiving routine clinical treatment and undergoing repeated clinical and high-frequency ultrasound assessments.

    Diagnostic Test: Serial High-Frequency Cutaneous Ultrasonography

Interventions

  • Diagnostic testSerial High-Frequency Cutaneous Ultrasonography

    Serial B-mode and color Doppler skin ultrasonography performed with the Clarius L20 (8-20 MHz) at days 0, 15, 30, 45, and 90 after initiation of clinically indicated treatment. This imaging procedure is for observation and does not determine drug allocation.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Clinical Cure

    Percentage of evaluable participants meeting the predefined clinical cure criteria at three months after completion of treatment, based on examination for complete re-epithelialization of ulcerative lesions and resolution or flattening of active inflammatory infiltration.

    Time frame: Three months after completion of routine treatment

Secondary outcomes

  1. Longitudinal Change in Dermal Thickness

    Serial ultrasound measurement of dermal thickness (mm) in the followed cutaneous lesion.

    Time frame: Days 0, 15, 30, 45, and 90 after treatment initiation

  2. Longitudinal Change in Sonographic Echogenicity

    Serial assessment of dermal and hypodermal lesion echogenicity on high-frequency ultrasound.

    Time frame: Days 0, 15, 30, 45, and 90 after treatment initiation

  3. Presence of Color Doppler Vascular Signal

    Presence or absence of detectable color Doppler signal within the studied lesion at each scheduled visit; Doppler settings will be standardized.

    Time frame: Days 0, 15, 30, 45, and 90 after treatment initiation

  4. Association Between Baseline Ultrasound and Histopathologic Features

    Exploratory assessment of associations between baseline sonographic morphological features and histopathological findings from the initially sampled lesion.

    Time frame: Baseline, prior to initiation of treatment

  5. Residual Ultrasound Abnormalities at Initial Clinical Cure Assessment

    Presence of persistent sonographic dermal, hypodermal, or vascular abnormalities at the visit when clinical cure is first identified.

    Time frame: At first documented clinical cure, within 12 months after treatment initiation

  6. Occurrence of Cutaneous Leishmaniasis Relapse

    Clinical recurrence of cutaneous leishmaniasis after documented initial cure; operational definition of confirmed relapse and at-risk follow-up to be finalized.

    Time frame: Up to 12 months after initiation of treatment

07

Study locations

1 of 1 sites recruiting
  • University Hospital of Brasilia - Leishmaniasis Outpatient Clinic
    Brasília, Federal District, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — deidentified study data will be published at dryad repository (https://datadryad.org/) after all publications related to the study are published

Supporting information: Study protocol

Time frame: after publication of results, one year after conclusion, abril 2029

Access criteria: Publicly evaluable, deidentified data

Data sharing details ↗ · datadryad.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Apr 2028, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 13, 2026
StartActual
Jan 8, 2025
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07934446
Lead sponsor
University of Brasilia
Responsible party
Sponsor
First posted
Nov 13, 2026
Start date
Jan 8, 2025
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Daniel Holanda Barroso, PhD
Contact
danielhbarroso@unb.br
+55 61 3107-3711
Daniel holanda Barroso, PhD
Contact
daniel.barroso@ebserh.gov.br
+5561 3107-3712
Neysa Aparecida Tinoco Regattieri
principal investigator · Universidade de Brasilia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion